Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan 29;4(2):260-81.
doi: 10.3390/jcm4020260.

HPV Carcinomas in Immunocompromised Patients

Free PMC article

HPV Carcinomas in Immunocompromised Patients

Nicole M Reusser et al. J Clin Med. .
Free PMC article


Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide and can result in pre-malignancies or overt malignancies of the skin and mucosal surfaces. HPV-related illnesses are an important personal and public health problem causing physical, mental, sexual and financial detriments. Moreover, this set of malignancies severely affects the immunosuppressed population, particularly HIV-positive patients and organ-transplant recipients. There is growing incidence of HPV-associated anogenital malignancies as well as a decrease in the average age of affected patients, likely related to the rising number of high-risk individuals. Squamous cell carcinoma is the most common type of HPV-related malignancy. Current treatment options for HPV infection and subsequent disease manifestations include imiquimod, retinoids, intralesional bleomycin, and cidofovir; however, primary prevention with HPV vaccination remains the most effective strategy. This review will discuss anogenital lesions in immunocompromised patients, cutaneous warts at nongenital sites, the association of HPV with skin cancer in immunocompromised patients, warts and carcinomas in organ-transplant patients, HIV-positive patients with HPV infections, and the management of cutaneous disease in the immunocompromised patient.

Keywords: carcinogenesis; human Immunodeficiency virus (HIV); human papillomavirus (HPV); immunosuppression; skin cancer; vaccine.

Similar articles

See all similar articles

Cited by 23 articles

See all "Cited by" articles


    1. Trottier H., Franco E.L. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(Suppl. S1):1–15. - PubMed
    1. Dunne E.F., Park I.U. HPV and HPV-associated diseases. Infect. Dis. Clin. N. Am. 2013;27:765–778. doi: 10.1016/j.idc.2013.09.001. - DOI - PubMed
    1. Chelimo C., Wouldes T.A., Cameron L.D., Elwood J.M. Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. J. Inf. 2013;66:207–217. doi: 10.1016/j.jinf.2012.10.024. - DOI - PubMed
    1. Soohoo M., Blas M., Byraiah G., Carcamo C., Brown B. Cervical HPV Infection in female sex workers: A global perspective. Open AIDS J. 2013;7:58–66. doi: 10.2174/1874613601307010058. - DOI - PMC - PubMed
    1. Palefsky J.M., Holly E.A., Ralston M.L., Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J. Infect Dis. 1998;177:361–367. doi: 10.1086/514194. - DOI - PubMed